Pancreatic Cancer Research

ResearcherGarvan Institute of Medical ResearchActive in the last 2 years

Robert Grützmann

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-2559-0476; OpenAlex author ID A5008757972, A5137699684. Sources: OpenAlex.

Their work

Papers
81 (first author 4, last author 10)
Trials
0
Grants
0
Labs led
2
Collaborators
228
Papers, trials and grants by year

2011: 4 papers · 2012: 4 papers · 2013: none · 2014: 4 papers · 2015: 3 papers · 2016: 1 paper · 2017: 3 papers · 2018: 4 papers · 2019: 10 papers · 2020: 4 papers · 2021: 8 papers · 2022: 10 papers · 2023: 4 papers · 2024: 7 papers · 2025: 9 papers · 2026: 6 papers

Papers 50 of 81

  1. Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.117035↗
  2. Enhancing multidisciplinary tumor board decision-making in pancreatic cancer using cinematic rendering. Co-author DOI 10.1016/j.pan.2025.12.025↗
  3. Prognostic impact of CRM-status on survival in patients with resected pancreatic adenocarcinoma - a dual-center cohort analysis. Co-author DOI 10.1016/j.suronc.2026.102422↗
  4. Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomi… Co-author DOI 10.1200/jco-25-03004↗
  5. Immune Cell-Specific and Isoform-Selective Regulation of CD44 in Pancreatic Ductal Adenocarcinoma Links Lymph Node Variant Loss and Exosomal CD44 to Clinical O… Co-author DOI 10.3390/cells15050411↗
  6. Post-Surgical Remodeling of Circulating Monocytes Identifies CD86 Expression on Non-Classical Monocytes as a Prognostic Indicator in Pancreatic Ductal Adenocar… Co-author DOI 10.3390/ijms27115012↗
  7. CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research. Co-author DOI 10.1016/j.semcancer.2025.07.004↗
  8. Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multic… Co-author DOI 10.1016/s2468-1253(25)00056-1↗
  9. Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by modulating KRAS-mediated survival pathw… Co-author DOI 10.1038/s41598-025-95766-5↗
  10. Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO… Co-author DOI 10.1200/jco-24-01502↗
  11. Impact of Structured Postoperative Surveillance on Survival in Patients with Resected Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers17091424↗
  12. Correction: Lan et al. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer. Cancers 2022, 14, 326. Co-author DOI 10.3390/cancers17193181↗
  13. The Prognostic Role of Para-Aortic Lymph Node Metastasis in Patients with Resected Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers17213418↗
  14. Increased Herpesvirus Entry Mediator Expression on Circulating Monocytes and Subsets Predicts Poor Outcomes in Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.3390/ijms26072875↗
  15. Identification of Cancer Associated Fibroblasts Related Genes Signature to Facilitate Improved Prediction of Prognosis and Responses to Therapy in Patients wit… Co-author DOI 10.3390/ijms26104876↗
  16. Prognostic role of nutrition parameters on short- and long-term outcome in patients with primary resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.clnesp.2024.06.002↗
  17. Recurrence pattern and its risk factors in patients with resected pancreatic ductal adenocarcinoma - A retrospective analysis of 272 patients. Last author DOI 10.1016/j.pan.2024.07.017↗
  18. Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. Co-author DOI 10.1038/s41420-024-01890-y↗
  19. CD71 expressing circulating neutrophils serve as a novel prognostic biomarker for metastatic spread and reduced outcome in pancreatic ductal adenocarcinoma pat… Co-author DOI 10.1038/s41598-024-70916-3↗
  20. Scribble Deficiency Promotes Pancreatic Ductal Adenocarcinoma Development and Metastasis. Co-author DOI 10.1158/0008-5472.can-23-3419↗
  21. Exosomal ROR1 in peritoneal fluid identifies peritoneal disseminated PDAC and is associated with poor survival. Co-author DOI 10.3389/fimmu.2024.1253072↗
  22. Neutrophil-to-Lymphocyte Ratio and Prognostic Nutritional Index Are Predictors for Overall Survival after Primary Pancreatic Resection of Pancreatic Ductal Ade… Co-author DOI 10.3390/cancers16162911↗
  23. Screening for pancreatic cancer in individuals with genetic susceptibility Co-author DOI 10.21037/hbsn-23-176↗
  24. Impact of Aspirin Intake on Postoperative Survival after Primary Pancreatic Resection of Pancreatic Ductal Adenocarcinoma-A Single-Center Evaluation. Co-author DOI 10.3390/biomedicines11051466↗
  25. Circulating Monocytes Serve as Novel Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.3390/cancers15020363↗
  26. Impact of CRISPR/Cas9-Mediated CD73 Knockout in Pancreatic Cancer. Co-author DOI 10.3390/cancers15194842↗
  27. [Pancreatic cystic space-occupying lesions-Diagnostics, treatment and follow-up care : Current recommendations taking the current German S3 guidelines on pancr… Last author DOI 10.1007/s00104-022-01616-9↗
  28. Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancr… Co-author DOI 10.1053/j.gastro.2022.07.047↗
  29. [Better Therapy for Pancreatic Cancer through More Radical Surgery?] Last author DOI 10.1055/a-1766-7643↗
  30. CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer. Co-author DOI 10.1186/s13046-022-02443-w↗
  31. An m5C methylation regulator-associated signature predicts prognosis and therapy response in pancreatic cancer. Co-author DOI 10.3389/fcell.2022.975684↗
  32. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer. Co-author DOI 10.3390/cancers14020326↗
  33. Genome-Wide CRISPR Screening Identifies DCK and CCNL1 as Genes That Contribute to Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.3390/cancers14133152↗
  34. Impact of Patient Age on Postoperative Short-Term and Long-Term Outcome after Pancreatic Resection of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14163929↗
  35. Identification of Genes Associated with Liver Metastasis in Pancreatic Cancer Reveals PCSK6 as a Crucial Mediator. Co-author DOI 10.3390/cancers15010241↗
  36. Time to Surgery Does Not Affect Overall or Disease-Free Survival of Patients with Primary Resectable PDAC. Co-author DOI 10.3390/jcm11154433↗
  37. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinica… Last author DOI 10.1007/s00066-020-01654-4↗
  38. R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-… First author DOI 10.1007/s00066-020-01680-2↗
  39. Impact of resection margin status on survival in advanced N stage pancreatic cancer - a multi-institutional analysis. Co-author DOI 10.1007/s00423-021-02138-4↗
  40. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2020.09.043↗
  41. Significance of Examined Lymph Node Number in Accurate Staging and Long-term Survival in Resected Stage I-II Pancreatic Cancer-More is Better? A Large Internat… Co-author DOI 10.1097/sla.0000000000003558↗
  42. Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials. Co-author DOI 10.1097/sla.0000000000005126↗
  43. Deep Learning Improves Pancreatic Cancer Diagnosis Using RNA-Based Variants. Co-author DOI 10.3390/cancers13112654↗
  44. Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cells10071821↗
  45. HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2020.107625↗
  46. [Indications for Surgery in Pancreatic Ductal Adenocarcinoma - Consensus Recommendations by the German Society for General and Visceral Surgery]. Co-author DOI 10.1055/a-1161-9501↗
  47. Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003143↗
  48. Upregulation of CD20 Positive B-Cells and B-Cell Aggregates in the Tumor Infiltration Zone is Associated with Better Survival of Patients with Pancreatic Ducta… Co-author DOI 10.3390/ijms21051779↗
  49. The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. Co-author DOI 10.1126/science.aaw3145↗
  50. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Co-author DOI 10.1136/gutjnl-2017-314828↗

Closest collaborators

The 25 strongest of 228 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Maximilian Brunner · 22 shared papers, 2019–2026 · strength 4.71
  2. Christian P. Pilarsky · 40 shared papers, 2011–2026 · strength 4.33
  3. Christian Krautz · 20 shared papers, 2011–2026 · strength 3.69
  4. Georg F. Weber · 19 shared papers, 2018–2026 · strength 3.68
  5. Anke Mittelstädt · 10 shared papers, 2022–2026 · strength 2.08
  6. Anne Jacobsen · 8 shared papers, 2020–2026 · strength 1.57
  7. Paul David · 7 shared papers, 2023–2026 · strength 1.34
  8. Nathalie Britzen‐Laurent · 8 shared papers, 2022–2025 · strength 1.28
  9. Bin Lan · 7 shared papers, 2019–2025 · strength 1.11
  10. Hai Yang · 8 shared papers, 2017–2024 · strength 1.00
  11. Waldemar H. Uhl · 7 shared papers, 2019–2026 · strength 0.89
  12. Frederik J. Hansen · 5 shared papers, 2023–2026 · strength 0.87
  13. Yanxi Lu · 4 shared papers, 2024–2025 · strength 0.84
  14. Isabelle Kuchenreuther · 4 shared papers, 2024–2026 · strength 0.80
  15. Danilo Hackner · 4 shared papers, 2022–2024 · strength 0.76
  16. Henriette Golcher · 5 shared papers, 2019–2026 · strength 0.67
  17. Sabine Semrau · 4 shared papers, 2021–2026 · strength 0.65
  18. Marius Distler · 7 shared papers, 2012–2022 · strength 0.63
  19. Michael B. Ghadimi · 5 shared papers, 2017–2026 · strength 0.63
  20. Helmut Oettle · 5 shared papers, 2017–2026 · strength 0.63
  21. Lisa-Sophie Arnold · 3 shared papers, 2024–2026 · strength 0.58
  22. Dorota Łubgan · 4 shared papers, 2019–2026 · strength 0.58
  23. Anke Reinacher‐Schick · 4 shared papers, 2019–2026 · strength 0.58
  24. Uwe A. Wittel · 4 shared papers, 2019–2026 · strength 0.58
  25. Andrew Victor Biankin · 5 shared papers, 2012–2025 · strength 0.58

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.